919 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Teva launches generic version of Merck cholesterol-lowering medicine http://feeds.bizjournals.com/~r/industry_6/~3/SyKuOF7Grag/teva-launches-generic-version-of-merck-cholesterol.html Jun 12, 2017 - Teva Pharmaceutical Industries Ltd. said Monday it has launched a generic version of the cholesterol lowering medication Zetia. Zetia, which contains the active ingredient ezetimibe, is a prescription medicine made by Merck (NYSE: MRK) used to lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol in the blood. Ezetimibe tablets are for patients who cannot control their cholesterol levels by diet and exercise alone. Teva said the product can be used by itself or with other…
Teva launches generic Zetia in U.S. https://seekingalpha.com/news/3272999-teva-launches-generic-zetia-u-s?source=feed_news_all Jun 12, 2017 - Teva Pharmaceutical Industries (TEVA +0.5%) launches its generic version of Merck's (MRK) cholesterol fighter ZETIA (ezetimibe) tablets in the U.S.According to IMS, the U.S. market is ~$2.7B.
How approval of a low-price generic HIV prevention drug could hit Gilead http://feeds.bizjournals.com/~r/industry_6/~3/foDxIjUlOXk/hiv-aids-truvada-prep-gilead-gild-teva-generic.html Jun 09, 2017 - Foster City's Gilead Sciences won approval in 2012 of Truvada as the first drug to prevent the spread of the AIDS virus. What does it mean now that Teva Pharmaceutical Industries has won the OK to introduce a supposedly low-cost version of the drug?
Teva to nominate new directors https://seekingalpha.com/news/3272529-teva-nominate-new-directors?source=feed_news_all Jun 09, 2017 - In the latest step toward remaking the company, Teva Pharmaceutical (NYSE:TEVA) will seek to overhaul its board by nominating four new directors.Among their first orders of business would be picking a
Teva Migraine Candidate Succeeds in Second Phase III Study http://feeds.benzinga.com/~r/benzinga/~3/eJwToD2AuG8/teva-migraine-candidate-succeeds-in-second-phase-iii-study Jun 08, 2017 -

Teva Pharmaceutical Industries Ltd. TEVA announced that its experimental migraine prevention drug, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.

read more

3 Reasons Teva Pharmaceutical Industries Ltd. Nosedived 12% in May https://www.fool.com/investing/2017/06/06/3-reasons-teva-pharmaceutical-industries-ltd-nosed.aspx?source=iedfolrf0000001 Jun 06, 2017 - Teva's rough year continues to get worse. Is there light at the end of the tunnel?
Regeneron Announces Positive Data on Carcinoma Candidate http://www.zacks.com/stock/news/263027/regeneron-announces-positive-data-on-carcinoma-candidate?cid=CS-ZC-FT-263027 Jun 05, 2017 - Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Teva's Migraine Candidate TEV-48125 Positive in Phase III http://www.zacks.com/stock/news/262725/tevas-migraine-candidate-tev-48125-positive-in-phase-iii?cid=CS-ZC-FT-262725 Jun 01, 2017 - Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).
Ohio blames drugmakers for fueling opioid crisis http://rss.cnn.com/~r/rss/money_topstories/~3/tLid9VvZ6yg/index.html Jun 01, 2017 - Read full story for latest details.
Teva's fremanezumab successful in late-stage migraine study; U.S. marketing application expected this year https://seekingalpha.com/news/3270722-tevas-fremanezumab-successful-late-stage-migraine-study-u-s-marketing-application-expected?source=feed_news_all May 31, 2017 - A Phase 3 clinical trial, HALO, assessing Teva Pharmaceutical Industries' (TEVA +0.5%) fremanezumab for the prevention of migraine met all primary and secondary endpoints. Patients treated with the mo

Pages: 1...7677787980818283848586...92

<<<Page 81>